最新文章
- Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China
- Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China
- Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress
- Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2022
- Antengene to Participate in Three Upcoming Investor Conferences in May/June
- Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting
- Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018
- Notice of the Annual General Meeting
- Form of Proxy for the Annual General Meeting
- Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-Election of Directors and Notice of Annual General Meeting
- 2021 ANNUAL REPORT
- Baird Biotech Discovery Series-Karyopharm Therapeutics Inc. (KPTI) & Antengene Corporation Limited
- Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
- XPOVIO®
- Antengene’s Pivotal “MARCH” Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine
- Podcast: Global Reach, Clinical Stage Assets, and a Revenue Stream – Antengene
- Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
- Change of Joint Company Secretary and Waiver from Strict Compliance with Rules 3.28 and 8.17 of the Listing Rules
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2022
- Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
- Voluntary Announcement – IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
- 2021 Annual Results Conference Call Deck
- Announcement of Annual Results for the Year Ended December 31, 2021
- Antengene Announces IND Approval in China for the Phase I Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
- Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
- Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
- Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting
- Voluntary Announcement – IND Approval in China for the Phase I Study of ATG-101 for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma
- Voluntary Announcement – TGA in Australia Approves Xpovio® (Selinexor) for Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma
- Notice of Date of Board Meeting
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 28 Feburary 2022
- Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
- Voluntary Announcement – Approval of NDA by the Singapore HSA for Xpovio® for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma in Three Indications
- Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma in Three Indications
- Next Day Disclosure Return
- Antengene Corporate Presentation
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2022
- Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
- Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037
- ADOPTION OF THE 2022 RESTRICTED SHARE UNIT SCHEME
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 14 January 2022)
- Next Day Disclosure Return
- 40th Annual J.P. Morgan Healthcare Conference Presentation
- Business Update Call on NMPA Granted Marketing Approval for XPOVIO (ATG-010/selinexor) in China
- 40th Annual J.P. Morgan Healthcare Conference Presentation
- Key Account Manager
- Digital Marketing
- Medical Science Liaison
- Medical Writer
- QA Manager
- (Senior) Clinical QC Specialist
- (Senior) Clinical Research Associate
- Clinical Trial Manager
- Discovery Biology Researcher/Scientist
- Discovery Biology Scientist
- Safety Physician
- Study Physician
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 7 January 2022)
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2021
- Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 6 January 2022)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 5 January 2022)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 4 January 2022)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 31 December 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 30 December 2021)
- R&D Day Mandarin Session2 – Live Webcast
- R&D Day Mandarin Session1 – Live Webcast
- R&D Day English Session – Virtual Conference
- Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
- Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 21 December 2021)
- Yilun Liu, MBA
- List of Directors and Their Roles and Functions
- List of Directors and Their Roles and Functions
- List of Directors and Their Roles and Functions
- Share Option Scheme
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 20 December 2021)
- Share Option Scheme
- Share Option Scheme
- First Patient Dosed in Australia in ATG-101 First-in-Human Trial
- ATG-010 SELINEXOR CHINA NMPA APPROVAL
- Antengene Announces NDA Approval by NMPA for XPOVIO®, China’s First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma
- Antengene and XtalPi Announce AI-Driven R&D Collaboration
- Voluntary Announcement – NMPA Granted Marketing Approval for Selinexor (ATG-010) in China
- List of Directors and Their Roles and Functions
- Resignation and Appointment of Non-Executive Director
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 16 December 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 15 December 2021)
- Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
- Next Day Disclosure Return
- Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo(nivolumab) in Advanced Solid Tumors
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 7 December 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 6 December 2021)
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2021
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 3 December 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 2 December 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 1 December 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 30 November 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 29 November 2021)
- Antengene Included in the MSCI Global Small Cap Indexes – MSCI China Index Constituent Stocks
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 24 November 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 18 November 2021, Resubmission)
- Next Day Disclosure Return
- Antengene Hosted R&D Day Highlighting Excellent Progress on its Vision to Build a Research-Driven, Global Oncology Company with a Robust Pipeline to Deliver Transformational Medicines to Treat Patients Beyond Borders Worldwide
- Antengene Announces IND Approval in China for a Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma
- Voluntary Announcement – Approval of the Phase I/II Study of Selinexor (ATG-010) in Patients with Non-Hodgkin Lymphoma in China
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 18 November 2021)
- Antengene Presents Compelling Preclinical Data on Two Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12, 2021
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 11 November 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 10 November 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 9 November 2021)
- Antengene to Release Preliminary Results of Phase 1b TOUCH Trial of Selinexor (ATG-010) for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 8 November 2021)
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2021
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 5 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 15 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 19 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 18 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 20 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 25 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 26 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 27 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 28 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 29 October 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 3 November 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 1 November 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 2 November 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 4 November 2021)
- Next Day Disclosure Return (Equity Issuer – Share Buybacks on 5 November 2021)
- Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
- Voluntary Announcement – Approval of NMPA for Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
- Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
- Voluntary Announcement – Antengene Received U.S. FDA Approval of IND for Phase I Trial Of ATG-101 in Solid Tumors and Non-Hodgkin Lymphomas
- Antengene to Host its First R&D Days on November 16 and November 18, 2021
- Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates
- Antengene to Present Data of Its PD-L1/4-1BB Bispecific Antibody ATG-101 and ERK1/2 Inhibitor ATG-017 at SITC 2021
- 2021 Interim Results Presentation
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2021
- Voluntary Announcement-Intention to Conduct on-Market Share Repurchase
- 2021 INTERIM REPORT
- Notification of Publication of 2021 Interim Report
- Antengene Selected as a Constituent of the FTSE Global Equity Index Series
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2021
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2021
- VOLUNTARY ANNOUNCEMENT-ACKNOWLEDGEMENT OF CTN BY THE TGA FOR PHASE I CLINICAL TRIAL OF ATG-101 IN SOLID TUMORS AND NON-HODGKIN LYMPHOMAS
- SUPPLEMENTAL ANNOUNCEMENT-CANCELLATION OF GRANT OF CERTAIN SHARE OPTIONS
- Antengene Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China
- VOLUNTARY ANNOUNCEMENT-APPROVAL OF THE PHASE II STUDY OF SELINEXOR BY NMPA FOR THE TREATMENT OF MYELOFIBROSIS IN CHINA
- ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2021
- Antengene and MindRank AI Enter into Collaboration to Advance the Development of Difficult-to-Drug Molecular Targets
- Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
- NOTICE OF DATE OF BOARD MEETING
- VOLUNTARY ANNOUNCEMENT-APPROVAL OF NDA BY THE MFDS FOR ATG-010 (SELINEXOR) FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND DIFFUSE LARGE B-CELL LYMPHOMA
- Antengene Announces The Approval by Human Research Ethics Committee in Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
- 2020 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
- Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies
- VOLUNTARY ANNOUNCEMENT-THE SUBMISSION OF NDA FOR SELINEXOR IN TAIWAN FOR THE TREATMENT OF THREE INDICATIONS IN HEMATOLOGIC MALIGNANCIES
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 June 2021
- Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)
- Donald Andrew Lung, J.D., MBA
- Kevin Lynch, M.D.
- Announcements and Notices – LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
- Announcements and Notices – (1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 18, 2021; (2) RETIREMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR; AND (3) APPOINTMENT OF EXECUTIVE DIRECTORS
- VOLUNTARY ANNOUNCEMENT AN UPDATE ON LATEST DEVELOPMENTS
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021
- Antengene Provides an Update on Its Latest Developments
- Founder and CEO of Antengene, Dr. Jay Mei, talks innovation in biotech, passion and learning from our mistakes
- Antengene’s Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS
- Country focus: China & APAC’s growing medical needs bring opportunities and challenges
- Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
- Notification Letter and Request Form to Non-Registered Shareholders
- REVISED FORM OF PROXY FOR THE 2020 ANNUAL GENERAL MEETING
- SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING
- SUPPLEMENTAL CIRCULAR PROPOSED ELECTION OF EXECUTIVE DIRECTORS AND SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING
- Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021
- Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021
- Kan Chen, Ph.D.
- ANNOUNCEMENT AND NOTICES-(1)RETIREMENT OF EXECUTIVE DIRECTOR AND NON-EXECUTIVE DIRECTOR (2)WITHDRAWAL OF ORDINARY RESOLUTIONS AT THE AGM (3)NOMINATION OF EXECUTIVE DIRECTORS AND (4)ADDITIONAL RESOLUTIONS TO BE PROPOSED AT THE AGM
- Antengene Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome
- Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development
- Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)
- VOLUNTARY ANNOUNCEMENT-ENTERING INTO WORLDWIDE EXCLUSIVE LICENSE AGREEMENT WITH CALITHERA BIOSCIENCES, INC.
- Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial
- Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies
- Antengene Announces the IND Approval for Eltanexor in Patients with Advanced Solid Tumors in Mainland China
- VOLUNTARY ANNOUNCEMENT-NMPA APPROVAL OF IND APPLICATION FOR A PHASE IB/II CLINICAL TRIAL OF ELTANEXOR IN ADVANCED SOLID TUMORS
- VOLUNTARY ANNOUNCEMENT-NMPA APPROVAL OF IND APPLICATION FOR A PHASE III CLINICAL TRIAL OF SELINEXOR IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER
- Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
- Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
- VOLUNTARY ANNOUNCEMENT – BUILDING OF THE DRUG DISCOVERY AND MANUFACTURING CENTER FOR ANTIBODY BIOLOGICS IN HANGZHOU QIANTANG NEW AREA
- Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment
- China Healthcare Industry Investment and Financing Honor List 2019– Medical and Health Companies with the Highest Investment Value
- The 4th Healthcare Investment ExcellentList—Annual Best Enterprise in Biopharmaceutical Industry 2020
- Future Healthcare VB 100 List 2019—TOP100
- Future Healthcare VB 100 List 2019—TOP10 Best-Performing CEOs
- CV Awards– The Best Investment Case in the Biopharmaceutical Field of 2019
- “Hurun” Top 100 Rising Star Enterprises with the Most Investment Value in China– Top 50 Zhejiang
- Shaoxing City Development Contribution Award 2018
- The ATG-008 project was selected as a Major Special Project for New Drug Creation in the 13th Five-Year Plan of the Ministry of Science and Technology 2018
- Antengene was selected as a Leading Introducing and Cultivating Innovation & Entrepreneurship Team in Zhejiang Province
- The ATG-008 project was selected as a Major Special Project for New Drug Creation in the 13th Five-Year Plan of the Ministry of Science and Technology 2019
- First Award of 6th Zhejiang China Innovation & Entrepreneurship Competition 2019
- First Award in Biopharmaceutical Industry of 8th China Innovation & Entrepreneurship Competition 2019
- China’s Pharmaceutical Innovative Enterprises 2020
- Dr. Jay Mei won the title of “2020 China Economic News Person · New Economic Leader”
- “The Most Popular New Stock Company Among Investors” at the 5th Annual Awards Ceremony of “Golden Hong Kong Stock”
- The 10th China Charity Festival “CSR Industry Model Award 2020”
- Treatment with Selinexor in Advanced Liposarcoma Demonstrates Clinically Important Reduction in Pain with Improved HRQoL Outcomes
- 2020 ANNUAL REPORT
- “APAC을 시작으로 글로벌 항암제 기업으로 거듭나겠다”…한국지사 설립한 안텐진 전략은
- PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE SHARES,RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
- NOTICE OF THE ANNUAL GENERAL MEETING
- “안텐젠은 BMS 등 투자로 2017년 설립된 탄탄한 회사”
- Aiming for an IPO, Antengene wants to be China’s Celgene
- 2020
- 2017
- 2021
- 2019
- 2018
- Antengene Announces Financial Results for Full Year 2020
- Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL
- Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations
- Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
- John F. Chin, MBA
- Bo Shan, Ph.D.
- VOLUNTARY ANNOUNCEMENT – NMPA APPROVAL OF IND APPLICATION FOR ATG-019 IN PATIENTS WITH ADVANCED SOLID TUMORS OR NON-HODGKIN’S LYMPHOMA
- Antengene Appoints Bo Shan as Chief Scientific Officer
- International Torch Study (ATG-008-HCC-001) Investigator Meeting held by Antengene
- Dr. Yijun Yang and Dr. Bo Shan joined Antengene Corporation
- Antengene and Karyopharm Sign Exclusive License Agreement to Develop and Commercialize Selinexor, Eltanexor, Verdinexor and KPT-9274 in China and Other Regions in Asia
- Antengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
- Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM
- Antengene Announces Acceptance of IND Application in China for a Phase 3 Clinical Trial of ATG-010 (Selinexor) in Combination with Bortezomib and Dexamethasone (SVd) for the Treatment of rrMM
- Jay Mei, M.D., Ph.D.
- Kevin Lynch, M.D.
- John F. Chin, MBA
- Donald Andrew Lung, J.D., MBA
- Yiteng Liu, M.Sc.
- Yijun Yang, Sc.D., Ph.D.
- Zhinuan Yu, Ph.D.
- Thomas Karalis, B.Sc.
- Shimin Sun, M.D., MPH
- Jay Mei, M.D., Ph.D.
- Mark J. Alles
- Jing Qian, M.Ec., MBA
- Sheng Tang, MBA
- Jeffrey Barrett, Ph.D.
- Joseph Camardo, M.D.
- Timothy Block, Ph.D.
- Robert Gale, M.D.
- Shaji Kumar, M.D.
- Thierry Facon, M.D.
- Florence Houn, M.D.
- Pharmaceutical Innovative Company of China in 2020
- 2019 China Healthcare Industry Investment and Financing Honor List
- Hurun China Future Unicorns 2019 Q2
- Hurun China Future Unicorns 2019 Q1
- China Future Healthcare Rankings 2019 Top 100 Pharma & Biotech Companies
- Future Medical Top 100 Pengcheng Award Annual Innovative Enterprise CEO in 2019
- Best Investment Case in Bio-pharmaceutical Industry of China Investment List in 2019
- Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang Province
- The Champion of the 6th Innovation & Entrepreneurship Competition of Zhejiang Province
- The Champion of the 8th National Leading Innovation and Entrepreneurship Competition
- Antengene Appoints Bo Shan as Chief Scientific Officer
- Antengene Appoints Kevin Lynch as Chief Medical Officer
- Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021
- Antengene Included in the Shenzhen-Hong Kong Stock Connect
- Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea
- Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
- Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China’s NMPA
- Antengene Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage
- Antengene Partners with SAP to Implement an Automated Digital Enterprise Management System
- Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM
- Antengene Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study
- Restore the core! Selinexor (ATG-010), a first-in-class drug for multiple myeloma, to be launched in Hainan Free Trade Port
- Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference
- Antengene Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer
- Antengene Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL
- Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
- Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology
- Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL
- Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), a Second Generation Selective Inhibitor of Nuclear Export (SINE), in Mainland China for the Treatment of Myelodysplastic Syndrome
- Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange
- Antengene’s New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer
- Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines
- Antengene Announces First Patient Dosing in a Phase I Trial of ATG-017 in Advanced Solid Tumors and Hematological Malignancies in Australia
- Antengene Announces First Patient Dosed with ATG-010 (selinexor) for Relapsed or Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma
- Antengene Announces IND Approval by NMPA to Initiate a Phase II Clinical Trial of ATG-008 for the Treatment of Advanced Solid Tumors with Specific Genetic Alterations
- Australian Therapeutic Goods Administration (TGA) Approves the First Phase I Trial of ATG-017 (ERK 1/2 inhibitor) for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies
- Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization
- Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development
- Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions
- Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer
- Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets
- Antengene Doses First Patient with ATG-008, a mTOR1/2 Dual-targeted Inhibitor, for Advanced Solid Tumors and Hepatocellular Carcinoma of the Clinical Trial with Junshi Biosciences’ Toripalimab
- Antengene Announces First Patient Dosed in China Registration Trial of ATG-010 (selinexor) for Relapsed or Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
- Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin’s Lymphoma
- Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
- Phase 2 clinical trial of ATG-008 as targeted therapy for advanced non-small-cell lung cancer initiated in China
- Phase 2 clinical trial of ATG-010 as targeted therapy for advanced non-small-cell lung cancer initiated in China
- Clinical trial of Antengene’s ATG-008 in combination with Junshi Biosciences’ Toripalimab for treatment of advanced solid tumors and hepatocellular carcinoma officially initiated
- Novel oral medication for diffuse large B-cell lymphoma! Another indication of XPOVIO®, a first-in-class nuclear export inhibitor, is expected to achieve accelerated approval
- Phase 3 Clinical Study of Novel Selective Inhibitor of Nuclear Export Selinexor with New Combination Therapy for Multiple Myeloma Meets Primary Endpoint
- News Express! The Clinical Trial of ATG-010 for Peripheral T-cell Lymphoma and NK/T-cell Lymphoma Has Been Approved
- Antengene Presented a Keynote Speech at J.P. Morgan Conference
- Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
- Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
- News Flash! The PAK4/NAMPT Dual Target Oral Inhibitor, ATG-019, Passed the Review of Investigational New Drug (IND) by Taiwan, China
- Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364
- Take the crown! — Antengene was awarded the first prize in the 8th China Innovation& Entrepreneurship Competition
- Latest Progress in the treatment of blood cancer with Selinexor, a selective inhibitor of nuclear export
- Karyopharm Announces FDA Approval of XPOVIO™ (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
- Antengene publishes clinical data on ATG-010 (Selinexor) for the treatment of refractory and/or relapsed multiple myeloma and relapsed diffuse large B-cell lymphoma at the Annual Meeting of Chinese Society of Clinical Oncology
- Antengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor
- Strong alliance for finding a new treatment of liver cancer: Antengene cooperates with Junshi Biosciences to conduct clinical research on the combination therapy of ATG-008 and Toripalimab to treat advanced liver cancer
- Antengene Corporation Announces Establishment of U.S. Subsidiary and Collaboration with the Baruch S. Blumberg Institute
- Antengene Team Standing Out as a Leader in Innovation and Entrepreneurship
- ATG-010, China’s first Selective Inhibitor of Nuclear Export obtains IND approval for the treatment of multiple myeloma
- Antengene Corporation Raises $120 Million in Series B Financing
- Antengene Corporation won the Project Support of “the 13th Five- Year National Major New Drug Development Project”
- Antengene Presents a Series of Reports on TORC1/TORC2 Dual-Targeted Inhibitor ATG-008 at the 21st Annual Meeting of Chinese Society of Clinical Oncology
- Karyopharm，Antengene Corporation’s Strategic Partner, Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor （ATG-010）as a Treatment for Patients with Penta-Refractory Multiple Myeloma
- Antengene launches patient enrollment for TORC1/2 dual-targeted inhibitor ATG-008 in Taiwan
- Antengene and WuXi STA announced a strategic cooperation in process R&D and manufacturing
- Antengene Corporation’s Strategic Partner, Karyopharm Therapeutics, Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma
- Antengene obtaining Korean IND approval for ATG-008, a mTOR Kinase Dual-Targeted Inhibitor
- ATG-008, China’s first TORC1/2 dual-targeted inhibitor of the new generation, has obtained IND approval
- Antengene Corporation Announces TFDA Approval of IND Application for a Phase II Study of ATG-008, a Next Generation mTOR Inhibitor, in Patients with Late-stage Hepatocellular Carcinoma (HCC)
- Antengene Corporation has submitted The Phase 2 Clinical Trial Application of ATG-008 to China, Taiwan and Korea
- Antengene Corporation attended Drug Development Case Study Workshop held by CFDA
- Antengene Corporation Attend the 20th Annual CSCO Meeting
- Antengene Corporation Attend Qiming Venture Partners CEO Summit
- Antengene Corporation Secures $21M in Series A Financing Round Led by Qiming Venture Partners
- Antengene announces China manufacturing plant in Shaoxing, China
- Celgene and Antengene Corporation Announced Long-term Collaboration and Celgene has Become Shareholder of Antengene
- PROCEDURES FOR SHAREHOLDERS TO PROPOSE A PERSON FOR ELECTION AS A DIRECTOR OF THE COMPANY
- Terms of Reference for the Remuneration Committee of Antengene Corporation Limited
- Terms of Reference for the Nomination and Corporate Governance Committee of Antengene Corporation Limited
- Terms of Reference for the Audit Committee of Antengene Corporation Limited
- SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
- LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
- ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020
- RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR
- LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
- NOTICE OF DATE OF BOARD MEETING
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
- Voluntary announcement – NMPA approval of IND application in China for ATG-010 (Selinexor) in combination with R-GDP (SR-GDP) for the Treatment of RRDLBCL in a global phase 2/3 study
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
- Voluntary announcement – FDA Approval of XPOVIO® (SELINEXOR) as a treatment for patients with multiple MYELOMA after at least one prior therapy
- Next Day Disclosure Return
- Voluntary announcement – Approval of IND application in China for a phase 3 clinical trial of ATG-010（Selinexor）
- Partial Exercise of The Over-allotment Option, Stabilizing Actions And End Of Stabilizing Period
- Voluntary announcement – The group’s domestic operating entity received government grant in the PRC
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
- Voluntary announcement – The submission of NDAS for XPOVIO® (SELINEXOR) in multiple APAC markets
- Voluntary announcement – The group’s domestic operating entity received government grant in the PRC
- Voluntary announcement – The Approval of clinical trial of ATG-016 for the treatment of MDS in the PRC
- Announcement of Offer Price and Allotment Results
- Terms of Reference for the Remuneration Committee of Antengene Corporation Limited
- Terms of Reference for the Nomination and Corporate Governance Committee of Antengene Corporation Limited
- Terms of Reference for the Audit Committee of Antengene Corporation Limited
- SIXTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
- LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
- Prospectus
- Formal Notice
- Application Form
- Therapeutic areas of our specialization and interests include but not limited to:
- We welcome discussions on strategic and creative collaborations in assets including:
- Antengene is committed to providing novel therapeutics to patients in Asia Pacific. We offer value-added partnership via leading complementary development in Asia while contributing to existing global development plans of our partners. We are also a regional partner for optimal commercialization with: